Kyntra Bio Inc (NASDAQ:KYNB) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Kyntra Bio Inc (NASDAQ:KYNB) has received a consensus rating of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $32.50.

Several brokerages have commented on KYNB. Rodman & Renshaw initiated coverage on Kyntra Bio in a research note on Tuesday, June 9th. They set a “buy” rating and a $30.00 target price on the stock. Oppenheimer assumed coverage on Kyntra Bio in a research note on Monday, July 6th. They issued an “outperform” rating and a $35.00 price target for the company. Finally, Weiss Ratings raised Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 14th.

Hedge Funds Weigh In On Kyntra Bio

A hedge fund recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC purchased a new stake in shares of Kyntra Bio Inc (NASDAQ:KYNB) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned about 0.26% of Kyntra Bio as of its most recent SEC filing. Institutional investors own 72.71% of the company’s stock.

Kyntra Bio Stock Up 6.1%

Shares of NASDAQ KYNB opened at $7.98 on Tuesday. Kyntra Bio has a twelve month low of $6.32 and a twelve month high of $12.60. The firm has a market cap of $32.32 million, a P/E ratio of 0.18 and a beta of 1.02. The company has a 50 day moving average of $7.15 and a 200 day moving average of $7.13.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.